International Lung Cancer Congress | Conference

Going Beyond PD-L1 for Predictive Biomarkers in Lung Cancer

August 15th 2016

Biomarkers, such as immune cell PD-L1 expression, mutational burden, and immune system activation should be investigated further to clarify the mechanisms behind response and nonresponse to immunotherapy in patients with lung cancer.

Biomarker-Driven Trials Set Pace in Lung Cancer

August 11th 2016

Biomarker-driven trials that include multiple substudies represent a new approach for investigating which patients with lung cancer are more likely to respond to different targeted therapies and are helping to set the pace throughout the oncology field.

Optimal Therapy Sequence Continues to Evolve for Advanced NSCLC

August 9th 2016

The past few years have seen rapid evolution in the treatment and handling of advanced non–small cell lung cancer, prompting questions on how to optimize immunotherapies and targeted agents as well as incorporate biomarker testing.

Liquid Biopsies Likely to Fill Many Roles in NSCLC Treatment

August 9th 2016

The optimal use of emerging assays that characterize molecular abnormalities from plasma in late-stage non–small cell lung cancer will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

Combination of Immunotherapy and Lung Cancer Therapies Potential Game-Changer, But Needs Further Research

August 9th 2016

Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.

CheckMate-026 Underscores Predictive Value of High PD-L1 Expression

August 9th 2016

The value of PD-L1 expression when using checkpoint inhibitors in non–small cell lung cancer is underscored by the just-announced disappointing progression-free survival findings from the phase III CheckMate-026 study of frontline nivolumab (Opdivo) versus physician's choice of combination chemotherapy.

Dr. Herbst on Next-Generation Agents in NSCLC

August 6th 2016

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor of Pharmacology, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, associate director for Translational Research, Disease Alligned Research Team Leader, Thoracic Oncology Program, Yale Cancer Center, discusses the next generation of agents coming down the pipeline in non–small cell lung cancer.

Dr. Gandara on Recent Advancements in Field of Lung Cancer

August 6th 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the most recent—and significant—advancements in the field of lung cancer.

ROS1, TRK Intriguing Targets for NSCLC

August 6th 2016

ROS1 and TRK are two emerging targets that have significant therapeutic promise for patients with non–small cell lung cancer, although they are not commonly considered while doing mutation testing.

Mok Predicts Practice-Changing Translational Advances in NSCLC

August 6th 2016

Tony Mok, MD, discussed translational advances on the horizon in non-small cell lung cancer during a presentation at the 2016 International Lung Cancer Congress.

Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC

August 5th 2016

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

Dr. Mok on Breakthrough Therapies for ALK-Positive NSCLC

August 5th 2016

Tony Mok, MD, professor of Medicine, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, discusses breakthrough therapies and ongoing trials for patients with ALK-positive non–small cell lung cancer.

Dr. Garon on Immunotherapy for Patients With NSCLC

August 5th 2016

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.

Dr. Hirsch on Importance of Molecular Testing in Lung Cancer

August 5th 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer, discusses the importance of molecular testing for patients with lung cancer.

New Immunotherapy Classes Emerge in Lung Cancer

August 4th 2016

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

Next-Generation ALK Inhibitors Effective in Patients With Brain Metastases

August 2nd 2014

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Dr. Vokes Discusses PARP Inhibitors in Lung Cancer

August 2nd 2014

Everett E. Vokes, MD, Giant of Cancer Care: Lung Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses PARP inhibitors as treatments for patients with lung cancer.

Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC

August 2nd 2014

Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.

Dr. Papadimitrakopoulou Discusses the Lung-MAP Trial

August 2nd 2014

Vassiliki Papadimitrakopoulou, MD, Professor, Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, discusses the Lung-MAP trial, which uses next-generation sequencing as a screening test rather than screening for one mutation.

Novel EGFR Specific Agents Impress in NSCLC

August 2nd 2014

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy